Regeneron Pharmaceuticals, Inc. has announced that it has been awarded a five-year grant from the National Institutes of Health as part of the NIH's Knockout Mouse Project. The goal of the Knockout ...

Regeneron will announce its earnings before the market opens on Thursday. ... It's called Velocigene, a method for quickly manipulating the genome of mice.

Nearly 1,800 employees—a large chunk of that workforce—walk through the doors of Regeneron Pharmaceuticals’ massive Tarrytown campus every day. ... each one of the cells of the newborn mice contains ...

Drugmaker Regeneron Pharmaceuticals, Inc. (REGN) said on Monday that it will acquire the assets of bankrupt biotechnology company 23andMe Holding Co. for $256 million. Regeneron intends to acquire ...

Regeneron purchased the pioneering company for $256 million at bankruptcy auction with the intent of using its genomic data to fuel drug discovery, the company said in a Monday statement.

Regeneron is down 31.4% since the beginning of the year, and at $490.50 per share, it is trading 59.2% below its 52-week high of $1,202 from August 2024.

Regeneron Pharmaceuticals and Mammoth Biosciences will collaborate to research, develop and commercialize gene editing therapies for multiple diseases, the companies said on Thursday.

A gene therapy from Regeneron Pharmaceuticals Inc. improved hearing in nearly all deaf children in a clinical trial, results that could allow the company to seek regulatory approval for the one ...

23andMe and its co-founder, Anne Wojcicki, aimed to revolutionize healthcare. Earlier this year, WSJ took a look at factors that knocked the company’s valuation down to nearly $0.

Regeneron Pharmaceuticals, Inc.'s rising shares and market cap, ... Regeneron invented VelociGene technology, ... So we're not really working with old-fashioned mice.

Regeneron gene therapy improves hearing in child. By Meghana Keshavan Oct. 27, 2023. Reprints. Hyacinth Empinado/STAT. Want to stay on top of the science and politics driving biotech today?

Regeneron Pharmaceuticals, Inc. has announced that it has been awarded a five-year grant from the National Institutes of Health as part of the NIH's Knockout Mouse Project. The goal of the Knockout ...